Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation

in: European journal of neuroscience | 2005

von Liu, F. | Grundke-Iqbal, I. | Iqbal, K. | +1

KTX 0101: A Potential Metabolic Approach to Cytoprotection in Major Surgery and Neurological Disorders

in: CNS drug reviews | 2005

von Smith, S. | Heal, D. | Martin, K.

Predictive Genetic Testing for Alzheimer's Disease: Impact upon Risk Perception

in: Risk analysis | 2005

von Marteau, T. | Roberts, S. | LaRusse, S. | +1

The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease

in: CNS drug reviews | 2003

von Rogawski, M. | Wenk, G.

Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach

in: Journal of neurochemistry | 2003

von Sergeant, N. | Bombois, S. | Ghestem, A. | +8

Pathogenic Aβ induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells

in: Journal of neurochemistry | 2003

von Jung, S. | Zhang, W. | Van Nostrand, W.

The Neurobiology and Neuropharmacology of Alzheimer's Disease The ASPET — Ray Fuller Symposium New Orleans, LA, USA, April 19 — 20, 2002

in: CNS drug reviews | 2002

von Scriabine, A.

Diagnosing and Treating Alzheimer's Disease: A Practitioner's Overview

in: Journal of the American Academy of Nurse Practitioners | 2002

von Schumann, L. | Langbart, C.

Galanin: Neurobiologic Mechanisms and Therapeutic Potential for Alzheimer's Disease

in: CNS drug reviews | 2001

von Counts, S. | Perez, S. | Kahl, U. | +6

Fifth Annual Promega Neurosciences Symposium: Gene Therapy Approaches to Neurodegenerative Disease Miami Beach, FL, November 6, 1999

in: CNS drug reviews | 2000

von Wartiovaara, K. | Hoffman, R. | Cosby, N.